Search results
Results from the WOW.Com Content Network
AstraZeneca plc (/ ˌæstrəˈzɛnəkə /) (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [2][3][4] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [5] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection ...
The Oxford–AstraZeneca COVID‑19 vaccine is used to provide protection against infection by the SARS-CoV-2 virus in order to prevent COVID-19 in adults aged 18 years and older. [1] The medicine is administered by two 0.5 ml (0.017 US fl oz) doses given by intramuscular injection into the deltoid muscle (upper arm).
Zeneca Group PLC. Zeneca (officially Zeneca Group PLC) was a British multinational pharmaceutical company headquartered in London, United Kingdom. It was formed in June 1993 by the demerger of the pharmaceuticals and agrochemicals businesses of Imperial Chemical Industries into a separate company listed on the London Stock Exchange. [1]
Sales in AstraZeneca's top business, oncology, grew 19% at constant currency rates to $5.33 billion and accounted for 41% of the total, while its rare disease and heart and kidney disease ...
LONDON -- I use a market statistics to identify shares for further research. Whatever the market conditions, stock-picking software will always identify a share worth buying. AstraZeneca is the ...
All of this means the company is gearing up for several launches and label expansions — and new revenue streams. AstraZeneca has set a target to become an $80 billion company, in sales, by 2030.
The UK's rollout was among the fastest in the world with among the highest uptake in its first few months, [2] although vaccination rates had slowed down or plateaued by autumn 2021 due to lower uptake in younger age groups. [5] [6] Polling suggests the UK's level of COVID-19 vaccine hesitancy is among the world's lowest. [7] [8]
(Reuters) -Britain's competition regulator is reviewing AstraZeneca's planned $39 billion takeover of U.S.-based Alexion on whether it could reduce competition in Britain or other markets. The UK ...